CN104983727A - Application of rotenone in preparation of drugs for reducing liver fat deposition - Google Patents
Application of rotenone in preparation of drugs for reducing liver fat deposition Download PDFInfo
- Publication number
- CN104983727A CN104983727A CN201510438340.7A CN201510438340A CN104983727A CN 104983727 A CN104983727 A CN 104983727A CN 201510438340 A CN201510438340 A CN 201510438340A CN 104983727 A CN104983727 A CN 104983727A
- Authority
- CN
- China
- Prior art keywords
- rotenone
- liver
- preparation
- application
- drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a novel application of rotenone in the preparation of drugs for reducing liver fat deposition. The rotenone can prominently reduce the liver fat deposition of patients with a nonalcoholic fatty liver disease. The invention provides a novel application of rotenone in the preparation of drugs for reducing the liver fat deposition of patients with a nonalcoholic fatty acid disease. A novel drug is provided for the patients with a nonalcoholic fatty acid disease, and the shortage of drug resistance of conventional drugs is overcome.
Description
Technical field
The present invention relates to rotenone and preparing the application in medicine, be specifically related to rotenone and reduce a kind of application newly in Liver fatty deposition medicine in preparation.
Background technology
Numerous clinical data display, in global range, the sickness rate of fatty liver constantly rises, and has become the second largest hepatopathy being only second to viral hepatitis.Fatty liver disease crowd occurred frequently mainly comprises overweight people, excessive consumption of alcohol person, diabetics, high fat diet person, less dynamic person, patients with chronic liver and person in middle and old age's endocrine patient.First three kind of groups is three large Etiologicals of fatty liver, and in diabetics, the sickness rate of fatty liver is up to 50%.
And fatty liver conditions patient utilizes Diet Therapy mostly at present, correct nutrient imbalance, control intake and low sugar, low fat, the Multivitamin of wine, and assisted movement conservative control improves.Drug therapy selectivity is little, not only will avoid the infringement of liver, also will reduce dose as far as possible.Because Lipoprotein Disorders relates to multifactor too many levels, it is not only reflected on circulating blood levels, also be reflected on tissue, cell and molecular level, after particularly noticing lipid peroxidation and inflammation and fibrosis relation, people try hard to find pharmaceutical intervention, regrettably there is no satisfied medicine clinically so far.Therefore, development of new reduces the key that the medicine of Liver fatty deposition is still Drug therapy.
Rotenone (rotenone), be a kind of colourless, the tasteless ketone crystalline compounds separated from natural plants also known as Radix Seu Caulis Millettiae Lasiopetalae (Tubatoxin), its structural formula is as follows:
Rotenone can extract from the seed of multiple pulse family and liana (such as Radix seu Caulis Derridis Trifoliatae), stem and root.Rotenone is a kind of specific inhibitor of mitochondrial respiratory chain cpd, have highly fat-soluble, do not need to rely on DAT and just can directly enter in kytoplasm, there is the activity suppressing mitochondrial complex I, activate AMPK, reduce effect of lipidosis.
Summary of the invention
The object of the invention is to provide rotenone to reduce the application in Liver fatty deposition medicine in preparation, thus provides a kind of new medicine, to improve the shortcoming that existing medicine easily produces drug resistance for this condition subject.
The technical solution adopted in the present invention is: rotenone reduces the application in Liver fatty deposition medicine in preparation.
Above-mentioned said application, concrete can be reduce the application in nonalcoholic fatty liver disease Liver fatty deposition medicine.
Further, what above-mentioned said application was concrete can be rotenone is made the compositions reducing Liver fatty deposition medicine.
Accompanying drawing explanation
The lower matched group db/db mouse liver inner lipid cavity of Fig. 1: HE dyeing
Db/db mouse liver inner lipid cavity after the lower rotenone administration of Fig. 2: HE dyeing
Fig. 3: the lower db/db mouse liver lactone of oil red dyeing drips
Fig. 4: after the lower rotenone administration of oil red dyeing, db/db mouse liver lactone drips
Detailed description of the invention
Unless otherwise defined, all technology of the present invention's use are identical with the implication that the technical field of the invention those of ordinary skill is understood usually with the implication of scientific terminology.Usually, the present invention use name and following experimental technique be all well known in the art or conventional.
In order to make technical problem solved by the invention, technical scheme and beneficial effect clearly understand, below in conjunction with specific embodiment, the present invention is further illustrated.In the present invention, rotenone is bought from sigma (article No. R8875); Db/db mice is bought from Shanghai Slac Experimental Animal Co., Ltd..
Embodiment 1
Rotenone significantly reduces the lipidosis of obesity mice liver
The fat db/db mice of extreme is divided into matched group and rotenone treatment group, often organizes 6.Under HE dyeing, the lipid cavity differed in size in a large number as seen in db/db mouse liver, as shown in Figure 1, liver tg content is 18.71 ± 2.45mg/g; Lumbar injection 1mg/kg rotenone considerably reduces the lipid cavity in db/db mouse liver after 2 weeks, as shown in Figure 2, liver tg content is 15.45 ± 1.88mg/g.
Embodiment 2
The fat db/db mice of extreme is divided into matched group and rotenone treatment group, often organizes 6.Under oil red dyeing, fat a large amount of as seen in db/db mouse liver drips, as shown in Figure 3; Lumbar injection 1mg/kg rotenone is after 2 weeks, and the fat almost can not seeing oil red dyeing in liver drips, as shown in Figure 4.
Should be noted that; although the present invention discloses as above with preferred embodiment; so itself and be not used to limit the present invention; anyly have the knack of this those skilled in the art; without departing from the spirit and scope of the present invention; any amendment of doing, equivalent replacement and improvement etc., all should be included within protection scope of the present invention.
Claims (2)
1. rotenone reduces the application in Liver fatty deposition medicine in preparation.
2. rotenone reduces the application in non-ethanol Patients with Fatty Liver Liver fatty deposition medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510438340.7A CN104983727A (en) | 2015-07-23 | 2015-07-23 | Application of rotenone in preparation of drugs for reducing liver fat deposition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510438340.7A CN104983727A (en) | 2015-07-23 | 2015-07-23 | Application of rotenone in preparation of drugs for reducing liver fat deposition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104983727A true CN104983727A (en) | 2015-10-21 |
Family
ID=54295718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510438340.7A Pending CN104983727A (en) | 2015-07-23 | 2015-07-23 | Application of rotenone in preparation of drugs for reducing liver fat deposition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104983727A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106491585A (en) * | 2017-01-06 | 2017-03-15 | 南京市儿童医院 | Application of the rotenone in fat and Fatty Liver Disease medicine is prepared |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101805333A (en) * | 2010-04-16 | 2010-08-18 | 湖南大学 | Cyclorotenoid, preparation method and application thereof |
| CN101904837A (en) * | 2010-07-31 | 2010-12-08 | 南京大学 | Use of rotenone as non-small cell lung cancer cell sensitizer |
| KR20150051429A (en) * | 2013-11-04 | 2015-05-13 | 아주대학교산학협력단 | Composition for preventing or treating obesity comprising Rotenone |
-
2015
- 2015-07-23 CN CN201510438340.7A patent/CN104983727A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101805333A (en) * | 2010-04-16 | 2010-08-18 | 湖南大学 | Cyclorotenoid, preparation method and application thereof |
| CN101904837A (en) * | 2010-07-31 | 2010-12-08 | 南京大学 | Use of rotenone as non-small cell lung cancer cell sensitizer |
| KR20150051429A (en) * | 2013-11-04 | 2015-05-13 | 아주대학교산학협력단 | Composition for preventing or treating obesity comprising Rotenone |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106491585A (en) * | 2017-01-06 | 2017-03-15 | 南京市儿童医院 | Application of the rotenone in fat and Fatty Liver Disease medicine is prepared |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017101878A4 (en) | Gynostemma pentaphyllum containing health care pharmaceutical composition for preventing hyperlipidemia, hypertension, hyperglycemia, and gout | |
| CN101695529A (en) | Compound Chinese herbal medicinal preparation for preventing and controlling bacterial enteritis, black gill and red skin disease of freshwater fish | |
| CN101708241B (en) | Medicinal composition for eliminating dampness and relieving itching | |
| CN104983727A (en) | Application of rotenone in preparation of drugs for reducing liver fat deposition | |
| CN104739840A (en) | Novel use of asiatic acid in preparation of drugs for preventing and treating hyperlipidemia and fatty liver | |
| CN103125628A (en) | Hypoglycemic tea | |
| CN102240345A (en) | Compound Chinese herbal medicine preparation for preventing and treating Newcastle disease | |
| CN102697771A (en) | New application of alpinetin | |
| CN102961447B (en) | Traditional Chinese medicine composition for promoting egg laying performance of laying hen in middle and later periods and preparation method thereof | |
| CN102145025B (en) | Pine pollen extract for treating fatty liver as well as preparation method and application thereof | |
| CN106727480B (en) | Fex-3 is preparing the application in anti-obesity drug | |
| CN101152196A (en) | Application of notoginsen triterpenes and its monomer in preparing medicament for treating melancholia | |
| EP3403664A1 (en) | Use ofcistanche tubulosa | |
| Srivastava et al. | Nutraceutical Potential of pumpkin (Cucurbita sp.) powder, seed, extracts, and oil on diabetes; Mini Review | |
| CN106822152B (en) | Pharmaceutical composition and application thereof | |
| CN103495115B (en) | A kind of to the medicative medicated wine of diabetes tool | |
| CN102342962A (en) | Application of extracts from Portulaca oleracea L. in preparation of anti-liver injury medicines and health foods | |
| CN102247572B (en) | Medicament for treating hyperlipidemia | |
| CN1736434A (en) | Throat comforting medicine with licorice and preparation process thereof | |
| CN103766453A (en) | Yam corn biscuit with health care effect on diabetes | |
| CN103961473A (en) | Liver protecting drug | |
| CN106309457B (en) | A kind of ursolic acid-Aspirin Conjugate is preparing the application in liver protecting drug | |
| CN106138031A (en) | MoracinC is used for the application treating in the medicine of diabetes in preparation | |
| CN106728645A (en) | A kind of Traditional Chinese medicine compound composition of domestic animal lactagogue | |
| CN1861072A (en) | Use of malic polyphenols for preparing medicines to treat bronchitis or asthma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151021 |